Efficacy and safety of lanthanoids as X-ray contrast agents

European Journal of Radiology

Volumn 80, Issue 2, 2011, Pages 349-356

  Pietsch, Hubertus ^a   Jost, Gregor ^a   Frenzel, Thomas ^a   Raschke, Marian ^a   Walter, Jakob ^a   Schirmer, Heiko ^a   Hütter, Joachim ^a   Sieber, Martin A ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Complex stability; CT contrast agents; Gadolinium; Lanthanoids; Nephrogenic systemic fibrosis (NSF)

Indexed keywords

CONTRAST MEDIUM; CYTOKINE; EUROPIUM PENTETIC ACID; GADOLINIUM PENTETIC ACID; HOLMIUM PENTETIC ACID; IODINE; LANTHANIDE; PENTETIC ACID; PRASEODYMIUM PENTETIC ACID; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHELATION; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); DRUG EFFICACY; DRUG SAFETY; IN VITRO STUDY; MASS SPECTROMETRY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN DEFECT; TECHNOLOGY; X RAY; X RAY TUBE;

ANIMALS; BIOPSY; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTRAST MEDIA; CYTOKINES; GADOLINIUM DTPA; IOHEXOL; LANTHANOID SERIES ELEMENTS; NEPHROGENIC FIBROSING DERMOPATHY; RATS; RATS, WISTAR; SKIN DISEASES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80053647690     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2009.10.023     Document Type: Article

References (24)

1. T. Grobner Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21 2006 3604 3605
2. P. Marckmann, L. Skov, and K. Rossen Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging J Am Soc Nephrol 17 9 2006 2359 2362 (Pubitemid 44300951)
3. A. Deo, M. Fogel, and S.E. Cowper Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure Clin J Am Soc Nephrol 2 2 2007 264 267
4. T.C. Lauenstein, K. Salman, and R. Morreira Nephrogenic systemic fibrosis: center case review J Magn Reson Imaging 26 5 2007 1198 1203 (Pubitemid 350058286)
5. R. Wertman, E. Altun, and D.R. Martin Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities Radiology 248 3 2008 799 806
6. M.R. Prince, H. Zhang, and M. Morris Incidence of nephrogenic systemic fibrosis at two large medical centers Radiology 248 3 2008 807 816
7. M.A. Sieber, H. Pietsch, J. Walter, W. Haider, T. Frenzel, and H.J. Weinmann A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media Invest Radiol 43 1 2008 65 75
8. M.A. Sieber, P. Lengsfeld, and J. Walter Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand J Magn Reson Imaging 27 5 2008 955 962 (Pubitemid 351614604)
9. M.A. Sieber, P. Lengsfeld, and T. Frenzel Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions Eur Radiol 18 10 2008 2164 2173
10. H. Pietsch, P. Lengsfeld, and T. Steger-Hartmann Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents Invest Radiol 44 4 2009 226 233
11. H. Pietsch, C. Pering, and P. Lengsfeld Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study J Magn Reson Imaging 30 2 2009 374 383
12. T.A. Hope, W.A. High, and P.E. Leboit Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron Radiology 2009
13. C.H. Evans Biochemistry of the lanthanides 1989 Plenum New York & London
14. T. Frenzel, P. Lengsfeld, H. Schirmer, J. Hutter, and H.J. Weinmann Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C Invest Radiol 43 12 2008 817 828
15. T. Steger-Hartmann, M. Raschke, B. Riefke, H. Pietsch, M.A. Sieber, and J. Walter The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide Exp Toxicol Pathol 2009
16. J.W. Crissman, D.G. Goodman, and P.K. Hildebrandt Best practices guideline: toxicologic histopathology Toxicol Pathol 32 1 2004 126 131 (Pubitemid 38250001)
17. P. Greaves Integumentary system 2000 Elsevier Amsterdam, London
18. A. Klein-Szanto, and C. Conti Skin and oral mucosa 2002 Academic Press San Diego, San Francisco
19. H. Pietsch, P. Lengsfeld, G. Jost, T. Frenzel, J. Hutter, and M.A. Sieber Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents Eur Radiol 19 6 2009 1417 1424
20. J.H. Distler, A. Akhmetshina, G. Schett, and O. Distler Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis Rheumatology (Oxford) 48 2 2009 98 103
21. J. Varga, and D. Abraham Systemic sclerosis: a prototypic multisystem fibrotic disorder J Clin Invest 117 3 2007 557 567 (Pubitemid 46348510)
22. H.P. Niendorf, A. Alhassan, V.R. Geens, and W. Clauss Safety review of gadopentetate dimeglumine. Extended clinical experience after more than five million applications Invest Radiol 29 Suppl. 2 1994 S179 S182
23. B. Tombach, C. Bremer, and P. Reimer Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study Radiology 218 3 2001 651 657 (Pubitemid 32172543)
24. J.C. Weinreb Which study when? Is gadolinium-enhanced MR imaging safer than iodine-enhanced CT? Radiology 249 1 2008 3 8